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Abstract 
Background: Primaquine is essential for the radical cure of vivax malaria, however its broad application is hindered 
by the risk of drug-induced haemolysis in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. 
Rapid diagnostic tests capable of diagnosing G6PD deficiency are now available, but these are not used widely.
Methods: A series of qualitative interviews were conducted with policy makers and healthcare providers in four 
vivax-endemic countries. Routine G6PD testing is not part of current policy in Bangladesh, Cambodia or China, but 
it is in Malaysia. The interviews were analysed with regard to respondents perceptions of vivax malaria, -primaquine 
based treatment for malaria and the complexities of G6PD deficiency.
Results: Three barriers to the roll-out of routine G6PD testing were identified in all sites: (a) a perceived low risk 
of drug-induced haemolysis; (b) the perception that vivax malaria was benign and accordingly treatment with 
primaquine was not regarded as a priority; and, (c) the additional costs of introducing routine testing. In Malaysia, 
respondents considered the current test and treat algorithm suitable and the need for an alternative approach was 
only considered relevant in highly mobile and hard to reach populations.
Conclusions: Greater efforts are needed to increase awareness of the benefits of the radical cure of Plasmodium vivax 
and this should be supported by economic analyses exploring the cost effectiveness of routine G6PD testing.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Almost three billion people are at risk for Plasmodium 
vivax infection globally [1, 2] and outside of Africa it is 
the predominant cause of malaria [3]. Although vivax 
malaria was once considered a benign infection, recent 
evidence suggests a considerable morbidity and mortal-
ity, associated mainly with anaemia due to recurrent epi-
sodes [4–6]. The propensity for P. vivax to relapse after 
prolonged periods of asymptomatic carriage undermines 
the patients and healthcare providers’ perceptions of the 
importance of radical cure, and this in turn confounds 
malaria control and elimination efforts.
Complete eradication of P. vivax will not be feasible 
without systematic treatment of the dormant liver forms 
(hypnozoites) of the parasite [7]. The only currently avail-
able treatment to kill hypnozoites is primaquine (PQ), 
an 8-aminoquinoline, which causes dose-dependent 
haemolysis in patients with inherited deficiency of the 
glucose-6-phosphate-dehyrdrogenase enzyme (G6PD) 
[8]. G6PD deficiency is the most common enzymopa-
thy worldwide, affecting approximately 400 million peo-
ple, the majority of whom are at risk for malaria [9]. To 
achieve effective radical cure, a sufficient total dose of 
PQ needs to be administered over a prolonged course, 
which is usually 14  days for G6PD-normal patients and 
weekly for 8 weeks for G6PD-deficient patients [10]. The 
WHO anti-malarial treatment guidelines were revised 
recently to recommend that wherever possible routine 
testing for G6PD deficiency should be undertaken prior 
to PQ-based radical cure. Implementing routine testing 
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for G6PD deficiency is challenging and the WHO guide-
lines also state that if testing is not available, an individ-
ual risk–benefit assessment should guide the decision 
whether to administer without testing or withhold PQ 
altogether [10].
Nearly all malaria-endemic countries in the Asia-
Pacific region have committed to malaria elimination by 
2030; however most of these countries do not test for 
G6PD deficiency on a routine basis and PQ is often not 
prescribed [11, 12]. The inclusion of primaquine into 
national treatment guidelines and its implementation 
will be essential to the successful elimination of malaria 
[7], G6PD testing is currently available in a number of 
formats [13, 14]. The gold standard test is by spectro-
photometry and flow cytometry. Although these tests 
quantify enzyme activity, they are expensive and require 
a well-functioning laboratory infrastructure. The most 
widely used qualitative test is the fluorescent spot test 
(FST) [15], which also requires laboratory infrastructure 
but comes at a considerably lower price and is easier to 
use. Despite its wide distribution the FST is not suited 
for remote locations without laboratory facilities and 
requires experience in its interpretation. A number of 
new lateral flow rapid diagnostic tests (RDT) for G6PD 
testing have been developed to overcome the challenges 
of the FST [16].
Primaquine radical cure has the potential to transform, 
the control and elimination of vivax malaria but its safe 
delivery will require building appropriate capacity to test 
G6PD status. The objective of this study was to assess 
key barriers to the introduction of routine G6PD testing 
through structured interviews with policy makers and 
healthcare providers in Bangladesh, Cambodia, China, 
and Malaysia.
Methods
Semi-structured interviews were conducted with key 
policy makers and healthcare personnel; all respondents 
were identified based on convenience sampling. Policy 
makers were defined as individuals who were actively 
involved in generating and updating national malaria 
treatment guidelines and health care providers were 
defined as individuals who applied the national malaria 
treatment guidelines to the clinical management of 
patients. Selection of policy makers was based on their 
involvement in malaria-related policy decisions and 
healthcare providers were selected based on their work 
experience.
Study sites
Sites were selected to reflect the variation in locations 
across Asia including a range of treatment policies. The 
study was conducted in four countries: Bangladesh, 
Cambodia, China, and Malaysia. The treatment guide-
lines for patients with vivax malaria in Bangladesh 
recommend 3  days of chloroquine (CQ) for P. vivax 
mono-infections, followed by 14  days of PQ (0.25  mg/
kg) without prior G6PD testing. In Cambodia, national 
guidelines recommend a unified treatment policy for 
all species using DHA–Piperaquine (DHA–PPQ) as 
schizontocidal treatment with PQ only prescribed 
after G6PD testing [17]. In China, CQ and 8 days of PQ 
(0.75 mg/kg) is recommended without prior G6PD test-
ing [11] and in Malaysia all malaria patients are admit-
ted to hospital, G6PD testing is routine, and patients are 
treated with CQ and, if G6PD normal, with 14 days of PQ 
(0.5 mg/kg) (Table 1) [11, 18].
Instrument development
Guides for the interviews were developed based on 
discussions between national malaria program offic-
ers, malaria researchers and healthcare providers [19]. 
The interviews for policy makers included questions on 
policy, operational, regulatory, financial, and managerial 
aspects of G6PD acceptability and testing. Interviews 
with healthcare providers provided additional perspec-
tives from the clinical environments. The focus of these 
interviews was to assess the practical application and fea-
sibility of G6PD testing, its roll-out and corresponding 
barriers (see Additional files 1, 2).
Data collection
Interviews were conducted in person in Bangladesh and 
Cambodia by local investigators familiar with the topic, 
whereas in China interviews were conducted by phone. 
In Malaysia, interviews were conducted in person by one 
of the US investigators with the support of local investi-
gators. All interviews were audio-taped, and field notes 
collected and written up on the day of the interview. 
Interviews were either conducted in the local language 
by local investigators and translated into English for 










Bangladesh [21] CQ PQ 14 days 
(0.25 mg/kg/day)
No
China [11] CQ PQ 8 days  
(0.75 mg/kg/day)
No
Cambodia [17] DHA–PPQ PQ 14 days  
(0.25 mg/kg/day)
Yes
Malaysia [18] CQ PQ 14 days  
(0.5 mg/kg/day)
Yes
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analysis (Bangladesh, Cambodia, China) or conducted in 
English (Malaysia). Summaries of findings were prepared 
and sent to each respondent for their feedback on docu-
mented material.
Data analyses
All interviews were transcribed and whenever not con-
ducted in English translated verbatim into English and 
coded using Nvivo version 11 (QSR International, Aus-
tralia). All transcripts were analysed by two researchers 
independently and the analyses compared. Transcripts 
were coded for knowledge and perceptions of vivax 
malaria, as well as for treatment practices and challenges 
associated with treatment. Additional categories were 
developed to capture the current practice of G6PD test-
ing, perceived usefulness of applied tests, acceptable price 
as well as for perceived knowledge gaps in regards to 
G6PD deficiency and its diagnosis. Passages of text were 
read and codes assigned based on themes, and examined 
for frequency, trends, similarities, and differences.
When necessary direct speech in the results section 
was corrected for grammatical errors to improve read-
ability; words added by investigators to improve clar-
ity were marked by hard brackets and omissions were 
marked by three consecutive dots. The addition and 
omission of words were discussed by investigators analys-
ing the data and were only retained if all agreed that the 
suggested change did not alter the sense of the respective 
sentence.
Research ethics
Verbal informed consent was obtained from all respond-
ents and participants received a translated information 
sheet containing details about the study, including its pro-
cedures to withdraw and measures to maintain confiden-
tiality. The protocol was approved by the Human Research 
Ethics Committee of the Northern Territory Department 
of Health and Menzies School of Health Research, Aus-
tralia (HREC 14.2312), the ethical committee of the Uni-
versity of San Francisco, California, USA (IRB# 14-15301) 
and the local ethical committees or comparable, respon-
sible authorities from each participating country (Inter-
national Centre for Diarrhoeal Research, Bangladesh 
(icddr,b); National Center for Parasitology Entomology 
and Malaria Control (CNM); Jiangsu Institute of Parasitic 
Diseases, China; Disease Control Division, Ministry of 
Health, Malaysia).
Results
Between May 2015 and October 2016, 44 interviews 
were conducted across the four countries included in the 
study. None of the designated interviewees at any of the 
sites refused to participate.
Bangladesh
A total of 11 interviews were conducted in Bangladesh 
of which nine were with healthcare providers from the 
Chittagong Hill Tracts where the majority of the coun-
try’s malaria is reported [20], and two with policy makers.
Perception of malaria
Almost all respondents acknowledged that there had 
been a reduction of clinical malaria over the last two 
decades and attributed this to the effectiveness of imple-
mented malaria control measures. Some respondents 
indicated that vivax malaria was no longer a public health 
priority.
“8-10 years back 70-80% of the hospitalized patients 
in Rangamati district were suffering from malaria. 
It was ranking first among the top ten diseases. Now 
it has changed a lot and we have controlled malaria 
significantly.’’ Healthcare provider
“No. I don’t see it [vivax malaria] as a problem here. 
Its proportion is very low.’’ Healthcare provider
There were mixed perceptions regarding the serious-
ness of vivax malaria amongst the respondents. While 
most respondents regarded vivax to be a benign disease, 
others highlighted its propensity to recur and its poten-
tial social and economic impact.
“Firstly it is a public health problem. Though vivax 
does not cause severe malaria as we all know, yet 
sufferers lose work hours, family earnings and 
health.’’ Healthcare provider
All respondents stated that they were aware of the con-
tent of the malaria treatment guidelines and that they 
adhered to it. The main challenges for the treatment of 
vivax malaria were described as: (a) difficulty in correctly 
diagnosing the species of infection by microscopy and 
therefore concern that some patients might receive the 
wrong treatment; (b) access to appropriate treatment in 
remote areas; (c) adherence to a 14-day regimen of pri-
maquine; (d) the usage of traditional medicine; and, (e) 
the lack of supply of anti-malarial drugs leading to stock 
outs in healthcare dispensaries.
“Yes there are challenges. For example, in my work-
ing area there are many hard to reach areas as well 
as never to reach areas.’’ Healthcare provider
“Patients often don’t want to complete the course [of 
PQ-based radical cure] after improving. We have to 
insist a lot. Moreover, locals believe in traditional 
treatments even after getting well with our treat-
ment. So we often say: ‘Go for your worshipping but 
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complete the medications” Healthcare provider
Respondents were aware of the risks of haemolysis 
after PQ treatment, however had not observed any cases 
in their daily practice.
“It is known that haemolysis can happen in case of 
G6PD-deficient person, but I have not seen such [a] 
patient yet…” Healthcare provider
Two interviewees stated that medical staff were often 
unaware about G6PD deficiency and that more training 
was needed.
“Even when I train medical officers, I find that many 
are not aware of G6PD deficiency and its conse-
quences. Not only … the public but [also] health pro-
fessionals in this district don’t know enough about 
G6PD deficiencies in Rangamati. So, there is a cer-
tain gap of knowledge.” Healthcare provider
Perceived need for G6PD testing
All respondent agreed that G6PD testing was not under-
taken in patients with vivax malaria prior to prescribing 
PQ; however many mentioned that access to G6PD test-
ing was desirable.
“Yes it would be [useful]. Not only for malaria, but 
it will help [raise] the persons aware[ness] on certain 
drug intake and food restrictions also. If tests could 
be made available, then, we could also evaluate the 
affordability of the tests and it could be helpful before 
treating with primaquine.” Healthcare provider
Cost and cost-effectiveness was stated by many 
respondents as the main barrier for the introduction 
of G6PD testing. Some thought that the test should be 
offered for free whereas others suggested a price in the 
range of 0.5–2.0 USD (40–150 BDT) per test.
“As I have mentioned before, we are a highly pop-
ulated and limited resourced country, so if the 
[G6PD] test could be made available in strip or RDT 
at less cost, then a lot of people can be benefitted.” 
Healthcare provider
“It [G6PD testing] should be free of cost like malaria 
RDT. People will not pay extra money to test G6PD 
when they are getting free [malaria] RDT and free 
treatment.” Healthcare provider
A recurring theme when talking about the introduction 
of G6PD testing was the need for appropriate training 
of healthcare staff and concern regarding the laboratory 
infrastructure required to provide this.
Perceived knowledge gaps around G6PD
Most respondents indicated a knowledge gap on the 
local prevalence and severity of G6PD deficiency. 
Respondents also reported a need for better pharma-
covigilance systems to monitor for severe haemolytic 
events.
“I think there should be a study in these areas to 
know about G6PD deficiency and side effects of pri-
maquine which we do not know. Then it will be pos-
sible to share it with the policy makers of the gov-
ernment.” Healthcare provider
One respondent felt poorly informed about the G6PD 
tests available and their respective performance and 
operational characteristics.
Cambodia
A total of 14 interviews were conducted in Cambo-
dia, eight with policy makers and six with healthcare 
providers.
Perception of malaria
Malaria was recognized by all policy makers and healthcare 
providers as an important problem in the country. Health-
care providers stated that there had been a reduction in the 
number of cases presenting to clinics over the last 10 years.
“Malaria is still a problem in this country but it seems 
to be dramatically decreased compared to the previ-
ous 10 years ago.” Policy maker
One respondent acknowledged that although falcipa-
rum cases had decreased while the proportion of vivax 
cases had increased.
“Yes it’s a problem, because before [there was]… a 
lot of Plasmodium falciparum but right now Plas-
modium vivax seems [to have] increased to 70% 
and Plasmodium falciparum [represents] only 20% 
[of malaria cases] and remaining are mixed [infec-
tions].” Policy maker
Most respondents were aware that schizontocidal 
treatment was ineffective for treating the dormant liver 
stages of P. vivax. Although national treatment guidelines 
recommended PQ after testing for G6PD, it was not used 
routinely. Some respondents were unfamiliar with the 
current national treatment guidelines.
“Primaquine was already there to be used to treat Pv 
[P. vivax] but the supplies… [have] not yet arrived, 
still in procurement process, so the NTG (treatment 
guidelines – the authors) …have not yet been fully 
implemented.” Policy maker
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“Yes we often have relapses with malaria by P. vivax. 
It’s too difficult to settle with patient. We know Plas-
modium vivax needs treatment by primaquine but 
don’t have any advice from the national programme. 
Patients lose faith in us.” Healthcare provider
There was a general awareness of the risks of PQ use 
in G6PD-deficient patients; however, some healthcare 
workers expressed that they lacked information and 
knowledge on G6PD deficiency.
“I don’t know [enough] as [I have] no guidance or 
training on G6PD.’’ Healthcare provider
“Never using G6PD test but have heard about this 
test.” Healthcare provider
Perceived need for G6PD testing
National Cambodian guidelines recommend that PQ 
treatment only be administered after testing for G6PD 
deficiency for vivax radical cure. The introduction of rou-
tine G6PD testing was therefore considered desirable by 
both policy makers and healthcare providers. A number 
of respondents stated that routine testing would be useful 
in the context of malaria elimination.
“For test[ing] G6PD[activity this] is very useful. I like 
G6PD test[ing] because when we use primaquine 
[the drug] can make blood damage, but if we do test 
before treatment and have problem with G6PD we 
can reduce [the] dose of primaquine.” Policy maker
“Very useful. If we have [a G6PD] test we expect [an 
improved]… treatment of vivax patients…better and 
join with malaria elimination.” Healthcare provider
Respondents stated that the cost and cost effectiveness 
of routine G6PD testing was an important barrier to its 
introduction, as was the need for additional training of 
healthcare staff.
“The price of [the] test should be subsidized…[so 
that] Cambodia can buy [the test].…The G6PD test 
must have price cheaper than price of malaria treat-
ment.” Policy maker
Two additional themes emerged when discussing the 
roll-out of routine G6PD testing: the need for community 
acceptance of G6PD testing and concerns regarding the 
feasibility of testing in the context of mass drug adminis-
tration (MDA).
“Providers, patients and communities must be well 
informed about the benefit of the G6PD test.” Policy 
maker
“For malaria elimination we need to apply MDA. So 
we discuss…the need to use test G6PD or not? … If 
[we] bring the test to rural areas [it] must [be] sim-
ple, easy to use.” Policy maker
China
In China, interviews were only conducted with policy 
makers. A total of six interviews were completed with 
policy makers from national, regional and technical levels.
Perception of malaria
All respondents acknowledged the Government’s efforts 
towards malaria elimination and stated that the burden of 
P. vivax had fallen but remained the predominant species 
of infection. Respondents mentioned the challenges in 
malaria control on endemic areas in the border regions.
“Malaria now is only reported in some border areas 
and with some imported cases. Malaria local trans-
mission is limited to the border area in Southern 
China since the National Malaria Elimination 
Campaign was launched in 2010, especially at the 
China-Myanmar border.” Policy maker
All respondents stated that they were aware of the 
national treatment guidelines and that these were 
adhered to. Respondents were also aware of the risks of 
haemolysis after PQ treatment and that this could be 
severe in G6PD deficient individuals. Other significant 
challenges to successful treatment included patients’ 
adherence to a full course of treatment.
Perceived need for G6PD testing
Many respondents considered that the medical history 
was sufficient to decide whether to treat with PQ and that 
G6PD testing was therefore not undertaken routinely.
“Currently, there is no compulsory test for G6PD 
before vivax treatment in the field, but vivax 
malaria patients will be asked whether they have 
a clinical history of broad bean haemolysis.” Policy 
maker
The usefulness of G6PD testing was mainly mentioned 
in the context of research.
“[G6PD testing] is conducted in some research study, 
especially in southern China, where G6PD deficiency 
was reported among minority groups.” Policy maker
Malaysia
In Malaysia a total of 13 interviews were conducted, four 
with policymakers and nine with healthcare providers 
from tertiary hospitals or outpatient clinics. Interviews 
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were conducted in six states: Selangor, Pahang, Kelantan 
and Perak in Peninsula Malaysia, and Sabah and Sarawak 
in Borneo.
Perception of malaria
Interviewees acknowledged the reduced burden of 
malaria and its geographic distribution within Malaysia.
“It [malaria] was [a problem]. But the problem is 
getting smaller. And now it’s localized to geographi-
cal regions and certain populations, at risk popula-
tions.” Policy maker
“It was a huge problem in the 1990s and I was 
working in a district. Oh no, it was in 1986…. and 
malaria was a big problem at that time. Along the 
way, things have improved.” Policy maker
Many acknowledged a shift in the proportion of 
infections due to different species. The emergence of P. 
knowlesi was also stated as a major area of concern.
“It shows that for vivax, the incidence is about 
the same, it actually went up a little for the last 
20 years. So the falciparum is the one coming down, 
so about 55-fold reduction in falciparum. So the 
one that actually overtaken falciparum and vivax is 
knowlesi. Knowlesi has overtaken both falciparum 
and vivax.” Healthcare provider
“Knowlesi no one knows how to control …but our 
malaria control is planned for other malaria but 
knowlesi, there is no game plan for knowlesi yet.” 
Healthcare provider
Interviewees considered other infectious diseases more 
important than malaria in some parts of the country.
“There is a significant proportion of malaria here 
[Borneo and Sabah] compared to the rest. In the 
Peninsula you have dengue being really, really big 
out there and it’s big over here but it’s the other way 
around for malaria. Dengue is a problem in Penin-
sula and malaria in Borneo.” Healthcare provider
A recurring theme among nearly all of the interview-
ees was the challenge posed by imported cases due to 
foreign workers. Ensuring adequate treatment, follow-up 
and adherence for both indigenous patients and migrant 
workers was acknowledged as a major problem.
“… even if you have like imported cases, they are 
very mobile. And some mobile populations. It’s very 
challenging to ensure that they are taking it [pri-
maquine] for 14 days. Either you need your staff to 
go there every day and like DOTS (directly observed 
treatment – the authors), you know, or you need to 
get [the mobile patients]. Get any other ways to know 
that how they take their medication for 14  days.” 
Policy maker
Malaria is a notifiable disease in Malaysia and patients 
diagnosed with malaria are followed up to ensure full 
recovery.
“Actually we monitor every case. Every single case of 
malaria in Malaysia. And every P. vivax…, every case 
reported for malaria in the district level, it will be 
notified to a system called E-Notification. And then 
they do case investigation for this case and then our 
team in the district health office will do investigation 
and then they will register these patients into another 
system called E-VEKPRO (…) So, we look every 
details about patients management.’’ Policy maker
Perceived usefulness of G6PD test
Respondents stated that G6PD testing by FST was per-
formed routinely for vivax patients and within the 
national new-born screening programme. G6PD defi-
ciency amongst the population living in malaria-endemic 
areas was perceived to be low:
“G6PD deficiency is very…it’s quite rare, you’ll see 
less than one patient a year” Healthcare provider
Despite perceptions of the low prevalence of G6PD 
deficiency, most respondents regarded the routine test-
ing for G6PD to guide PQ treatment as convenient and 
acceptable.
“We understand when to start the primaquine and 
avoid the adverse reactions, so its…I would say that 
it’s useful and its mandatory to know…” Healthcare 
provider
Interviewees reported that the results of a newborn 
G6PD deficiency screening were recorded on a card 
and handed to the parent, nevertheless many felt that 
patients were often unaware of these results or had lost 
the recorded result. Hence most interviewees empha-
sized the need to redo G6PD testing in all vivax patients 
independent of earlier results or the availability of results 
from newborn screening:
“We perform G6PD testing at birth and it is our 
practice to repeat the G6PD [test] prior to serving 
the primaquine. Once we know the patient have 
vivax and need primaquine…our G6PD test comes 
back within a day so there’s never been a delay of 
serving the primaquine because of G6PD [testing].” 
Healthcare provider
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One interviewee stated that he would administer PQ-
based radical cure to his patients while waiting for a 
G6PD test result:
“In fact, sometimes, when I see vivax patients I start 
primaquine right away. I just give it while waiting 
for test results, it won’t kill the patient. Nothing hap-
pens.” Healthcare provider
Perceived need for better G6PD tests
The majority of respondents did not know which test was 
used in routine practice, however some correctly men-
tioned the FST and considered its operational character-
istics to be favourable:
“It’s a very simple, fast test. I can get the results on 
the same day. It doesn’t sound very complicated to 
me. It’s easily available.” Healthcare provider
“It’s convenient, it does the job…it does the job of 
finding out for me who is G6PD [deficient]…that’s it.” 
Healthcare provider
While most respondents did not perceive an urgent 
need for improved G6PD tests, some raised concerns 
over the sensitivity and specificity of the FST.
“The qualitative test comes with an element of false 
positives and false negatives, and come in as equivo-
cal.” Healthcare provider
One provider raised the issue about objectiveness in 
the reading of the FST.
“I used to be quite unhappy with the G6PD screen-
ing test because there are too many positives and it’s 
based on just the fluorescent spots so the interpre-
tation is very subjective so that’s my main problem 
with the G6PD test.” Healthcare provider
Some mentioned the benefits of spectrophotometry or 
flow cytometry as a diagnostic tool that provides quantita-
tive results rather than qualitative results, but also acknowl-
edged that for most patients this might not be needed.
“I guess all tests have their limitations so certain con-
ditions where the heterozygous females, people worry 
you might [be] miss[ing] by the screening test.” Health-
care provider
After describing the benefits of a RDT, some interview-
ees suggested that a respective assay would be helpful for 
patient management in remote regions.
“Yes, yes in the field [an RDT could be useful]. In 
places which are further away from the major hos-
pitals or health clinics, then yes. In the tertiary set-
ting, I think the information we have is good enough.” 
Healthcare provider
In general there was a consensus that in the current 
situation and with regards to cost constraints, there was 
no immediate need for the introduction of point-of-care 
tests for routine settings.
“…there are a lot of point-of-care tests but you have 
to evaluate how the point-of-care test will add value 
to management and also consider cost effective-
ness. So if its life saving, then sure but for the ease of 
patient coming back for results, of course it will be 
an added benefit for point-of-care test but most of 
our malaria patients are in-patient so they won’t be 
walking around. I mean if I had unlimited resources, 
a point-of-care test would be great but if I had to 
choose, a G6PD point-of-care test will not be the first 
thing to come to my mind.” Healthcare provider.
Discussion
This study aimed to understand the perceived need for 
routine G6PD testing prior to PQ-based radical cure and 
identify key barriers to the introduction of routine G6PD 
testing.
In Bangladesh and China, PQ treatment is provided 
without prior G6PD testing [21]. In contrast, Cambodia 
has G6PD testing prior to PQ administration included in 
the national guidelines, but neither testing nor treatment 
is currently provided on a routine basis [17, 21]. Malaysia, 
where PQ is provided on a routine basis to vivax patients 
following G6PD testing [18], was included in the study 
as a comparator and to understand satisfaction with the 
currently used test format and how satisfied health care 
providers were with the current testing procedures.
In Bangladesh, Cambodia and China three key barriers 
impeding the introduction of routine G6PD testing prior 
to PQ based radical cure were identified.
1. Perceived low risk of primaquine‑induced haemolysis
The risk of PQ-induced haemolysis was considered to 
be low and this was a significant factor for the perceived 
need to test a patients G6PD status; treatment provid-
ers from Bangladesh were not aware of any case with PQ 
induced haemolysis. There are several plausible expla-
nations for the perception of low haemolytic risk of PQ 
treatment. In remote areas patients may not be able to 
return to the healthcare facility despite significant drug-
induced haemolysis, and thus significant haemolysis may 
have gone undetected. Alternatively poor adherence to 
treatment [22–25] could have resulted in patients receiv-
ing only low doses of PQ with minimal haemolytic risk. 
If the prevalence of G6PD deficiency was very low, or 
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the local variant conferred only a mild and self-limiting 
haemolysis then patients with clinically significant hae-
molysis would be rare or unlikely to seek further medi-
cal attention. Alternatively, the protective effect of G6PD 
deficiency against a P. vivax infection could be sufficiently 
high to result in low numbers of patients with G6PD 
deficiency being exposed to drug-induced haemolysis. 
In Malaysia the prevalence of G6PD deficiency was con-
sidered low, however healthcare providers still adhered 
to the national testing algorithm. Indeed contrary to the 
other countries, the G6PD status of a patient was consid-
ered “mandatory to know”, with much stricter adherence 
to the national guidelines.
2. Plasmodium vivax is considered “benign” or of very low 
incidence
In general, respondents regarded P. vivax infections as 
benign and/or of low incidence, whereas other commu-
nicable and non-communicable diseases were regarded 
as higher priority. In Bangladesh, Cambodia and China 
the declining incidence of P. vivax highlighted the success 
of national malaria programmes, but such success may 
have paradoxically undermined elimination efforts due to 
reduced awareness of the disease and subsequent funding 
cuts. This paradox has been proposed as a key reason why 
the first Global Malaria Eradication Programme (GMEP) 
ultimately failed [26]. However in Malaysia where there 
has been a major decrease in the reported burden of dis-
ease, the elimination path has not been impeded. Patients 
diagnosed with malaria are admitted to hospital until 
schizontocidal treatment is completed. All respondents 
from Malaysia were aware of the challenges of elimina-
tion settings, the threat of imported malaria and the need 
for sustained public control efforts.
3. Routine G6PD testing generates additional costs
The perceived low prevalence of G6PD deficiency 
and reduced incidence of P. vivax infection lead many 
respondents to question the cost-effectiveness of routine 
G6PD testing. In countries with limited public health 
resources this issue is critical for the implementation of 
routine testing. Regional or country-specific cost-benefit 
analyses [27], such as one recently conducted in Brazil 
[28] will be key to encouraging policymakers to invest 
adequately in routine G6PD testing. Respective economic 
studies are currently underway in a number of countries 
in Asia [29]. A recent analysis of data gathered from the 
Thai–Myanmar border suggested that routine testing had 
the potential to reduce total healthcare costs [30].
In Malaysia FST testing prior to PQ treatment is rec-
ommended and newborn babies are routinely screened 
for G6PD deficiency. Respondents believed that the cur-
rent practice of admitting all patients diagnosed with 
malaria to hospital for treatment was an effective strat-
egy. Only providing PQ once a patients’ G6PD status was 
known was considered practical and feasible.
Although newborn infants are screened for G6PD defi-
ciency in Malaysia, most interviewees emphasized that 
those results are rarely referred to, since patients cards 
are often missing or unavailable for older patients born 
before the introduction of newborn screening. Further-
more, G6PD enzyme activity may be elevated in early 
life and this may mask G6PD deficiency. Re-testing of 
patients irrespective of the result of the newborn screen-
ing is therefore beneficial to patients [31].
Some interviewees highlighted that a limitation 
of the FST test was its subjective interpretation and 
low performance. While currently available RDTs for 
G6PD have comparable performance to the FST [16, 
32], their operational characteristics are more favour-
able to the FST. Most currently available G6PD RDTs 
do not require a cold chain or laboratory infrastruc-
ture [33, 34], and can be undertaken at the bed-side 
on an individual basis (point-of-care). In contrast, the 
FST requires laboratory facilities and is generally run 
in batches for multiple patients; as the incidence of 
malaria falls, such batch testing will no longer be eco-
nomical. Although test results for RDTs are available at 
the bedside, most Malaysian respondents did not see a 
particular benefit in replacing the currently used FST 
by a RDT. The advantage of instant test results could 
be more relevant for marginalized groups, including 
those living in remote areas or for migrant workers 
with limited access to the health system where admis-
sion to hospitals is difficult and follow-up is limited. 
The benefits of rapid results were also mentioned by 
Cambodian respondents in the context of MDA, a set-
ting where instant results are needed and easy-to-use 
tests warranted.
The study has a number of limitations. Firstly par-
ticipants were selected through convenient sampling, 
an approach which was justified by the small number 
of interviewees and the specific technical knowledge 
required. Furthermore summaries of all interviews were 
sent back to interviewees for approval which was agreed 
during the approval for the study. However in no case 
were the summaries altered. Secondly the proportions 
of policy decision makers and healthcare providers var-
ied from country to country and a variety of interview 
methods were deployed including in-person, by phone, 
in English or the local language. Whilst these may have 
influenced the comparison of data between countries, 
they were consistent within country and are unlikely to 
have affected the main barriers identified. Thirdly whilst 
our findings are limited to four Asian countries the key 
barriers identified are likely to be generalizable to other 
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locations in vivax endemic countries although further 
studies are warranted to confirm this.
In conclusion the findings of the study highlight the 
need for greater awareness of the importance of P. vivax 
radical cure and the risks of PQ induced haemolysis. 
Cost-effectiveness and cost-benefit studies on the intro-
duction of routine G6PD testing in P. vivax-endemic 
settings, with complementary information on the local 
prevalence and genetic variants of G6PD deficiency will 
be critical in helping policymakers to prioritize limited 
resources. Strengthening pharmacovigilance systems to 
monitor the haemolytic risks associated with primaquine 
will also prepare malaria control programmes for the 
introduction of other 8-aminoquinolone based treat-
ment options with easier treatment schedules and the 
enhanced malaria control strategies needed to achieve 
the elimination of P. vivax.
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